Prevalence and factors associated with poor performance in the 5-chair stand test: findings from the Cognitive Function and Ageing Study II and proposed Newcastle protocol for use in the assessment of sarcopenia.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
04 2021
Historique:
revised: 08 11 2020
received: 25 08 2020
accepted: 24 11 2020
pubmed: 20 1 2021
medline: 29 10 2021
entrez: 19 1 2021
Statut: ppublish

Résumé

Poor performance in the 5-chair stand test (5-CST) indicates reduced lower limb muscle strength. The 5-CST has been recommended for use in the initial assessment of sarcopenia, the accelerated loss of muscle strength and mass. In order to facilitate the use of the 5-CST in sarcopenia assessment, our aims were to (i) describe the prevalence and factors associated with poor performance in the 5-CST, (ii) examine the relationship between the 5-CST and gait speed, and (iii) propose a protocol for using the 5-CST. The population-based study Cognitive Function and Ageing Study II recruited people aged 65 years and over from defined geographical localities in Cambridgeshire, Newcastle, and Nottingham. The study collected data for assessment of functional ability during home visits, including the 5-CST and gait speed. We used multinomial logistic regression to assess the associations between factors including the SARC-F questionnaire and the category of 5-CST performance: fast (<12 s), intermediate (12-15 s), slow (>15 s), or unable, with slow/unable classed as poor performance. We reviewed previous studies on the protocol used to carry out the 5-CST. A total of 7190 participants aged 65+ from the three diverse localities of Cognitive Function and Ageing Study II were included (54.1% female). The proportion of those with poor performance in the 5-CST increased with age, from 34.3% at age 65-69 to 89.7% at age 90+. Factors independently associated with poor performance included positive responses to the SARC-F questionnaire, physical inactivity, depression, impaired cognition, and multimorbidity (all P < 0.005). Most people with poor performance also had slow gait speed (57.8%) or were unable to complete the gait speed test (18.4%). We found variation in the 5-CST protocol used, for example, timing until a participant stood up for the fifth time or until they sat down afterwards. Poor performance in the 5-CST is increasingly common with age and is associated with a cluster of other factors that characterize risk for poor ageing such as physical inactivity, impaired cognition, and multimorbidity. We recommend a low threshold for performing the 5-CST in clinical settings and provide a protocol for its use.

Sections du résumé

BACKGROUND
Poor performance in the 5-chair stand test (5-CST) indicates reduced lower limb muscle strength. The 5-CST has been recommended for use in the initial assessment of sarcopenia, the accelerated loss of muscle strength and mass. In order to facilitate the use of the 5-CST in sarcopenia assessment, our aims were to (i) describe the prevalence and factors associated with poor performance in the 5-CST, (ii) examine the relationship between the 5-CST and gait speed, and (iii) propose a protocol for using the 5-CST.
METHODS
The population-based study Cognitive Function and Ageing Study II recruited people aged 65 years and over from defined geographical localities in Cambridgeshire, Newcastle, and Nottingham. The study collected data for assessment of functional ability during home visits, including the 5-CST and gait speed. We used multinomial logistic regression to assess the associations between factors including the SARC-F questionnaire and the category of 5-CST performance: fast (<12 s), intermediate (12-15 s), slow (>15 s), or unable, with slow/unable classed as poor performance. We reviewed previous studies on the protocol used to carry out the 5-CST.
RESULTS
A total of 7190 participants aged 65+ from the three diverse localities of Cognitive Function and Ageing Study II were included (54.1% female). The proportion of those with poor performance in the 5-CST increased with age, from 34.3% at age 65-69 to 89.7% at age 90+. Factors independently associated with poor performance included positive responses to the SARC-F questionnaire, physical inactivity, depression, impaired cognition, and multimorbidity (all P < 0.005). Most people with poor performance also had slow gait speed (57.8%) or were unable to complete the gait speed test (18.4%). We found variation in the 5-CST protocol used, for example, timing until a participant stood up for the fifth time or until they sat down afterwards.
CONCLUSIONS
Poor performance in the 5-CST is increasingly common with age and is associated with a cluster of other factors that characterize risk for poor ageing such as physical inactivity, impaired cognition, and multimorbidity. We recommend a low threshold for performing the 5-CST in clinical settings and provide a protocol for its use.

Identifiants

pubmed: 33463015
doi: 10.1002/jcsm.12660
pmc: PMC8061374
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

308-318

Subventions

Organisme : Medical Research Council
ID : G0601022
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9901400
Pays : United Kingdom
Organisme : Medical Research Council
ID : G06010220
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© 2021 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Int J Epidemiol. 2013 Dec;42(6):1640-8
pubmed: 23143611
J Cachexia Sarcopenia Muscle. 2019 Oct;10(5):1143-1145
pubmed: 31661195
J Am Geriatr Soc. 2016 Oct;64(10):2042-2050
pubmed: 27549914
J Geriatr Phys Ther. 2017 Oct/Dec;40(4):223-226
pubmed: 27805924
J Am Geriatr Soc. 2009 Feb;57(2):251-9
pubmed: 19207142
Lancet. 2013 Oct 26;382(9902):1405-12
pubmed: 23871492
Braz J Phys Ther. 2014 Mar-Apr;18(2):99-110
pubmed: 24839043
J Am Med Dir Assoc. 2015 Apr;16(4):323-8
pubmed: 25523286
Percept Mot Skills. 2006 Aug;103(1):215-22
pubmed: 17037663
Age Ageing. 2008 Jul;37(4):430-5
pubmed: 18487264
Clin Rehabil. 2012 Jul;26(7):656-63
pubmed: 22234904
Psychol Med. 1986 Feb;16(1):89-99
pubmed: 3515380
J Cachexia Sarcopenia Muscle. 2016 Mar;7(1):28-36
pubmed: 27066316
BMJ. 2010 Sep 09;341:c4467
pubmed: 20829298
Value Health. 2018 Sep;21(9):1104-1114
pubmed: 30224116
BMJ. 2014 Apr 29;348:g2219
pubmed: 24787359
Clin Rehabil. 1998 Oct;12(5):434-40
pubmed: 9796934
Eur Geriatr Med. 2020 Jun;11(3):433-441
pubmed: 32297269
Age Ageing. 2014 Jul;43(4):571-5
pubmed: 24855113
Maturitas. 2011 Jul;69(3):208-19
pubmed: 21596497
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Phys Ther. 2017 Sep 1;97(9):926-943
pubmed: 28605481
Res Q Exerc Sport. 1999 Jun;70(2):113-9
pubmed: 10380242
J Gerontol. 1994 Mar;49(2):M85-94
pubmed: 8126356
Scand J Med Sci Sports. 2001 Oct;11(5):280-6
pubmed: 11696212
BMC Geriatr. 2019 Jan 23;19(1):20
pubmed: 30674278
J Am Med Dir Assoc. 2019 Sep;20(9):1182-1183
pubmed: 31455509
Int J Chron Obstruct Pulmon Dis. 2015 Dec 03;10:2619-26
pubmed: 26664110
J Cachexia Sarcopenia Muscle. 2017 Apr;8(2):229-237
pubmed: 27897431
J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):62-68
pubmed: 31886632
J Neurosurg Spine. 2018 Oct;29(4):380-387
pubmed: 29957147
J Bone Miner Res. 2008 Jul;23(7):1037-44
pubmed: 18302496
Spinal Cord. 2013 Mar;51(3):214-7
pubmed: 23147127
J Gerontol A Biol Sci Med Sci. 2015 Jul;70(7):885-91
pubmed: 25394617
BMC Geriatr. 2018 Mar 22;18(1):79
pubmed: 29566673
Am J Med. 1985 Jan;78(1):77-81
pubmed: 3966492
J Am Med Dir Assoc. 2018 Aug;19(8):685-689
pubmed: 29778639
J Gerontol A Biol Sci Med Sci. 2002 Aug;57(8):M539-43
pubmed: 12145369
Rev Bras Ter Intensiva. 2019;31(1):27-33
pubmed: 30892478
Int Psychogeriatr. 2011 Sep;23(7):1152-9
pubmed: 21489342
J Cachexia Sarcopenia Muscle. 2021 Apr;12(2):308-318
pubmed: 33463015
BMC Geriatr. 2020 Mar 25;20(1):113
pubmed: 32213165
Percept Mot Skills. 1995 Feb;80(1):163-6
pubmed: 7624188
J Am Geriatr Soc. 1993 Jan;41(1):6-10
pubmed: 8418126

Auteurs

Richard Matthew Dodds (RM)

AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK.

James C Murray (JC)

AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK.

Antoneta Granic (A)

AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK.

Christopher Hurst (C)

AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK.

Germaine Uwimpuhwe (G)

Department of Anthropology, Durham University, Durham, UK.
Durham Research Methods Centre, Durham University, Durham, UK.

Sarah Richardson (S)

AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK.

Carol Brayne (C)

Cambridge Public Health, School of Clinical Medicine, University of Cambridge, Cambridge, UK.

Fiona E Matthews (FE)

Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.

Avan A Sayer (AA)

AGE Research Group, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, UK.
NIHR Newcastle Biomedical Research Centre, Newcastle University and Newcastle upon Tyne NHS Foundation Trust, Newcastle, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH